DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer
JM D'Antonio, DJ Vander Griend… - Endocrine-related …, 2009 - erc.bioscientifica.com
The peroxisome proliferator-activated receptor-γ (PPARγ) is a member of the nuclear
hormone receptor superfamily. Ligand activation of PPARγ is associated with differentiation …
hormone receptor superfamily. Ligand activation of PPARγ is associated with differentiation …
The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer
OBJECTIVES: To summarize the debate regarding use of intermittent androgen suppression
therapy in the treatment of prostate cancer originally presented at the 2007 Spring Meeting …
therapy in the treatment of prostate cancer originally presented at the 2007 Spring Meeting …
Long‐term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33‐month observational study
NA Spry, DA Galvão, R Davies, S La Bianca… - BJU …, 2009 - Wiley Online Library
OBJECTIVE To investigate changes in bone mineral density (BMD) and osteoporosis, over 3
years of intermittent androgen‐suppression therapy (IAST). PATIENTS AND METHODS This …
years of intermittent androgen‐suppression therapy (IAST). PATIENTS AND METHODS This …
A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: oncological results
D Prapotnich, X Cathelineau, F Rozet, E Barret… - World journal of …, 2009 - Springer
Objective To present oncological results with intermittent androgen deprivation (IAD) in a
single center. Methods Between 1992 and 2008, 566 patients with prostate cancer (PC) …
single center. Methods Between 1992 and 2008, 566 patients with prostate cancer (PC) …
Sexual functioning of Latino women seeking outpatient gynecologic care
KL Hullfish, LM Pastore, AJA Mormon… - The journal of sexual …, 2009 - academic.oup.com
Introduction A sample of Latino women from an ambulatory obstetrics and gynecology
(Ob/Gyn) clinic were queried about their sexual functioning using the Changes in Sexual …
(Ob/Gyn) clinic were queried about their sexual functioning using the Changes in Sexual …
局限性晚期前列腺癌间歇性内分泌治疗的临床观察
潘铁军， 刘波， 沈国球， 文翰东， 凃忠， 郭骏… - 现代泌尿生殖肿瘤 …, 2009 - cqvip.com
目的探讨局限性晚期前列腺癌间歇性内分泌治疗的效果. 方法选取局限性晚期(T3a, T3b)
前列腺癌患者24 例, 全雄性激素阻断治疗6-9 个月, 停药时机为PSA≤ 0.2 ng/ml 后, 持续3-6 …
前列腺癌患者24 例, 全雄性激素阻断治疗6-9 个月, 停药时机为PSA≤ 0.2 ng/ml 后, 持续3-6 …
前列腺癌内分泌治疗的历史与现状
赵欣， 马建辉 - 癌症进展, 2009 - cqvip.com
自1941 年Huggins 等通过临床研究率先证实应用雌激素或/和手术去势治疗晚期前列腺癌(
prostatecancer, PC) 有良好的效果以来, Pc 的内分泌治疗至今已有68 年. PC …
prostatecancer, PC) 有良好的效果以来, Pc 的内分泌治疗至今已有68 年. PC …
Intermittent hormone therapy and its place in the contemporary endocrine treatment of prostate cancer
G Shaw, RTD Oliver - Surgical Oncology, 2009 - Elsevier
Castration results in dangerous and disabling side effects. Deferred hormone therapy has
been shown to be associated with decreased survival. Intermittent hormone therapy (IHT) …
been shown to be associated with decreased survival. Intermittent hormone therapy (IHT) …
比卡鲁胺治疗进展期前列腺癌52 例
张建平， 林宗明， 刘宇军， 张立， 王国明 - 中国新药杂志, 2009 - cqvip.com
目的: 探讨比卡鲁胺治疗前列腺癌的疗效和安全性. 方法: 2006 年7 月1 日至2008 年6 月30
日间, 以我科收治的不能根治的52 例前列腺癌患者为对象, 全部患者至少符合下述1 个条件 …
日间, 以我科收治的不能根治的52 例前列腺癌患者为对象, 全部患者至少符合下述1 个条件 …
前列腺癌内分泌治疗现状与研究进展
周晓光， 张杰 - 世界临床药物, 2009 - cqvip.com
前列腺癌是欧美国家男性最常见的恶性肿瘤, 其在我国发病率呈逐年上升趋势.
内源性糖皮质激素水平在前列腺癌的发生发展中发挥重要作用, 内分泌疗法一直是临床治疗 …
内源性糖皮质激素水平在前列腺癌的发生发展中发挥重要作用, 内分泌疗法一直是临床治疗 …